Type-I diabetes aggravates post-hemorrhagic stroke cognitive impairment by augmenting oxidative stress and neuroinflammation in mice.
Animals
Cerebral Hemorrhage
/ chemically induced
Cognitive Dysfunction
/ chemically induced
Diabetes Mellitus, Experimental
/ chemically induced
Diabetes Mellitus, Type 1
/ chemically induced
Hand Strength
/ physiology
Inflammation Mediators
/ metabolism
Locomotion
/ drug effects
Male
Maze Learning
/ physiology
Mice
Mice, Inbred C57BL
Oxidative Stress
/ physiology
Streptozocin
/ toxicity
Stroke
/ chemically induced
Cognitive impairment
Diabetes
HMGB1
ICH
Neuroinflammation
Journal
Neurochemistry international
ISSN: 1872-9754
Titre abrégé: Neurochem Int
Pays: England
ID NLM: 8006959
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
received:
16
06
2021
revised:
29
07
2021
accepted:
31
07
2021
pubmed:
5
8
2021
medline:
5
2
2022
entrez:
4
8
2021
Statut:
ppublish
Résumé
Diabetes Mellitus (DM) is a major comorbid condition that increases susceptibility to stroke. Intracerebral hemorrhage (ICH), a devastating type of stroke, accounts for only 13% of the total stroke cases but is associated with higher mortality. Multimorbid models of DM and ischemic stroke have been widely studied; however, fewer pieces of evidence are available on the impact of DM on the outcomes of ICH injury. In this study, we investigated the effect of DM on ICH-induced injury and cognitive impairments. Streptozotocin (STZ) induced type-I DM (T1DM) animal model was used, and experimental ICH was induced by intrastriatal injection of collagenase. Our results demonstrated that DM is associated with a significant increase in hematoma volume and deficits in post-stroke locomotor, sensorimotor, and cognitive behavior in mice. The levels of neuroinflammation, oxidative/nitrosative stress, and glial cell activation were also increased in the diabetic mice following ICH injury. This study provides a better understanding of the influence of DM comorbidity on hemorrhagic stroke outcomes and uncovers the important pathological mechanisms underlying DM-induced exacerbation of ICH injury.
Identifiants
pubmed: 34348124
pii: S0197-0186(21)00197-2
doi: 10.1016/j.neuint.2021.105151
pmc: PMC8387457
mid: NIHMS1731269
pii:
doi:
Substances chimiques
Inflammation Mediators
0
Streptozocin
5W494URQ81
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
105151Subventions
Organisme : NINDS NIH HHS
ID : R01 NS112642
Pays : United States
Organisme : NIDDK NIH HHS
ID : R15 DK103196
Pays : United States
Informations de copyright
Copyright © 2021 Elsevier Ltd. All rights reserved.
Références
Brain Pathol. 2014 Sep;24(5):475-93
pubmed: 24571080
Brain Res. 2009 Jul 14;1280:148-57
pubmed: 19464275
Exp Neurol. 2019 Jan;311:106-114
pubmed: 30243988
Sci Rep. 2017 Apr 10;7:46243
pubmed: 28393932
Transl Stroke Res. 2020 Aug;11(4):762-775
pubmed: 31792796
Stroke. 2011 Dec;42(12):3587-93
pubmed: 21998050
Acta Neurochir Suppl. 2011;111:173-8
pubmed: 21725751
Exp Ther Med. 2018 May;15(5):4131-4138
pubmed: 29725362
Brain Res. 2014 Jul 7;1571:25-38
pubmed: 24814387
J Vis Exp. 2013 May 29;(75):e2609
pubmed: 23748408
Diabetologia. 2009 Aug;52(8):1665-8
pubmed: 19455302
Neurol Sci. 2016 Aug;37(8):1253-9
pubmed: 27115896
Neurosurg Focus. 2012 Apr;32(4):E8
pubmed: 22463118
Lancet. 2009 May 9;373(9675):1632-44
pubmed: 19427958
FASEB J. 2019 Aug;33(8):9616-9626
pubmed: 31145859
Front Cell Neurosci. 2014 Oct 31;8:355
pubmed: 25400546
Brain Res Bull. 2016 Jun;124:269-77
pubmed: 27233782
Int J Mol Sci. 2021 Jan 29;22(3):
pubmed: 33572986
Stroke. 2015 Aug;46(8):2302-4
pubmed: 26130090
J Neurotrauma. 2013 Aug 15;30(16):1434-41
pubmed: 23510201
Diabetes. 2002 Apr;51(4):1076-82
pubmed: 11916928
Neurol Sci. 2015 Jun;36(6):927-34
pubmed: 25560535
Clin Neurol Neurosurg. 2014 Mar;118:37-43
pubmed: 24529227
Stroke. 2014 Jul;45(7):2107-14
pubmed: 24916913
Obesity (Silver Spring). 2016 Feb;24(2):417-23
pubmed: 26694743
Crit Care Med. 2003 May;31(5):1482-9
pubmed: 12771622
J Neuropathol Exp Neurol. 2011 Mar;70(3):218-35
pubmed: 21293296
Brain Res. 2010 Jan 8;1306:131-41
pubmed: 19822133
Diabetologia. 2005 Feb;48(2):351-60
pubmed: 15688208
J Clin Invest. 1969 Nov;48(11):2129-39
pubmed: 4241908
Stroke. 2003 Sep;34(9):2215-20
pubmed: 12907821
Aging Dis. 2018 Jun 1;9(3):453-466
pubmed: 29896433
Circulation. 2019 Mar 5;139(10):e56-e528
pubmed: 30700139
Diabetes. 2004 Feb;53(2):454-62
pubmed: 14747298
Endocrinology. 2012 Jan;153(1):362-72
pubmed: 22109883
Eur J Pharmacol. 2018 Dec 5;840:50-59
pubmed: 30336136
Behav Brain Res. 2003 Feb 17;139(1-2):139-55
pubmed: 12642185
Diabet Med. 2005 Oct;22(10):1401-7
pubmed: 16176203
Cardiovasc Diabetol. 2012 Mar 07;11:21
pubmed: 22397368
Prog Neurobiol. 2014 Apr;115:25-44
pubmed: 24291544
Neuroscience. 2012 Jan 27;202:58-68
pubmed: 22178606
Diabetes Care. 2012 Oct;35(10):2076-82
pubmed: 22688551
Stroke. 2018 Oct;49(10):2453-2463
pubmed: 30355111
Mol Brain. 2016 Jan 28;9:11
pubmed: 26822304
CNS Neurol Disord Drug Targets. 2021;20(4):312-326
pubmed: 33622232
Nat Protoc. 2006;1(1):7-12
pubmed: 17406205
Mediators Inflamm. 2010;2010:
pubmed: 20936104
Stroke. 2005 Jan;36(1):86-91
pubmed: 15550687
Neuroscience. 2018 Jul 15;383:33-45
pubmed: 29746992
J Neurol Sci. 2007 Apr 15;255(1-2):90-4
pubmed: 17350046
Open Life Sci. 2018 Apr 10;13:77-81
pubmed: 33817071
Behav Brain Res. 2017 Mar 1;320:412-419
pubmed: 27818237
Pharmacol Rep. 2007 Nov-Dec;59(6):656-63
pubmed: 18195454
Sci Rep. 2018 May 29;8(1):8319
pubmed: 29844451
Exp Neurol. 2011 Dec;232(2):143-8
pubmed: 21884699
Clin Exp Immunol. 2006 Dec;146(3):443-7
pubmed: 17100763
Brain Res. 2020 Feb 15;1729:146600
pubmed: 31843625